Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active ingredient in Myfortic, is an immunosuppressant presented as an oral tablet for oral use. It is employed to reduce the risk of organ transplant rejection by inhibiting lymphocyte proliferation in transplant recipients and to support long‑term graft survival under medical supervision.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide. The company provides reliable sourcing, regulatory documentation, and logistics support to meet the needs of healthcare providers across multiple continents.

Myfortic, an antimetabolite immunosuppressant, is used to prevent rejection in various solid‑organ transplant procedures.

Kidney transplantation: reduces the incidence of acute rejection and supports long‑term graft function. Liver transplantation: helps maintain hepatic graft viability by suppressing immune‑mediated injury. Heart transplantation: lowers the risk of rejection episodes and contributes to improved survival rates.

Myfortic may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: feeling of sickness or urge to vomit. - Diarrhea: loose, frequent stools. - Abdominal pain: discomfort or cramping in the stomach area. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count leading to fatigue. - Severe infections: opportunistic infections such as CMV or bacterial sepsis. - Hepatic toxicity: elevated liver enzymes or liver injury.

Before initiating Myfortic therapy, clinicians should consider several precautionary measures to ensure patient safety. - Monitor blood counts: perform regular complete blood count tests to detect leukopenia or anemia. - Assess renal function: evaluate kidney function and adjust dose if impairment is present. - Avoid use in pregnancy: drug is classified as Category D; discontinue if pregnancy occurs. - Counsel on infection risk: advise patients to report fever, cough, or signs of infection promptly. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Myfortic can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Cyclosporine: increases mycophenolate exposure, raising toxicity risk. - Tacrolimus: synergistic immunosuppression may lead to excessive immune suppression. - Antacids containing aluminum or magnesium: reduce mycophenolate absorption, decreasing effectiveness.

Moderate Interactions (Monitor Closely): - Azathioprine: combined use may cause additive bone‑marrow suppression. - Rifampin: induces metabolism, lowering mycophenolate blood levels. - Live vaccines: heightened risk of infection due to immunosuppression.